entertainment -WSS

entertainment

author：knowledge 2025-09-02 05:43:56 - browse：4

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

explore

WSS

Just how do doctors, lawmakers, and the public define abortion?

First medicine developed to treat MASH expected to be approved soon

The Readout: Amylyx, Alumis, and Lundbeck drug updates

Novo Nordisk obesity pill bests Wegovy in early trial

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Just how do doctors, lawmakers, and the public define abortion?

Wikipedia

entertainment

entertainment

Medicare details structure of new drug price negotiation program

Headspace, Meta partner to launch VR meditation app for Quest

Heart attack and stroke risk calculators need revising

In 'major milestone,' FDA approves first cell therapy for solid tumors

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

CDC marks new Covid

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

The problem with charging patients to message their doctors

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Medicare Advantage enrollment grows 7.1% to 33.4 million people

leisure time

Headspace, Meta partner to launch VR meditation app for Quest

In his State of the Union, Biden takes clear aim at 'Big Pharma'

Air quality improving but still lags in Black, Hispanic communities

Readout LOUD podcast: Venture capital turmoil, obesity drug competition

Sen. Paul opposes bill to ban Chinese biotechs

Measles policy set amid Florida outbreak alarms vaccine proponents

leisure time

explore

entertainment

focus